Oxylipin profiling of human plasma reflects the renal dysfunction in uremic patients

Effects of hemodialysis on plasma oxylipins

“…We first determined the total levels of oxylipins in plasma of the HD patients (Table 2) and compared the results with the healthy control subjects. We were particularly interested in 9,10-EpOME, 12,13-EpOME, 5,6-DHET, and 5-HETE, which have been recently identified as the key markers to discriminate uremic ESRD patients from controls (Hu, 2018). Our results confirm these findings.…”

“…Despite significant changes in fatty acids signatures between healthy persons and CKD patients, we observed that hemodialysis does not alter plasma or RBC fatty acid levels to potentially explain the observed changes of oxylipins in the present study (Gollasch, 2020). Our data support the idea that 9,10-EpOME, 12,13-EpOME, 5,6-DHET, and 5-HETE are key markers to discriminate ESRD patients from healthy controls (Hu, 2018). It is unlikely that these changes occurred in response to chronic dialysis treatment since altered levels in 9,10-EpOME, 12,13-EpOME, 5,6-DHET, and 5-HETE levels were observed in patients with CKD before starting renal replacement therapy (Hu, 2018).…”

“…They could exhibit either beneficial or harmful cardiovascular effects (Afshinnia, 2018;Fan & Roman, 2017;Schunck, 2018). Oxylipin profiling of human plasma in uremic ESRD patients before fistula construction surgery has been reported (Hu, 2018). The authors identified decreases in 5,6-dihydroxyeicosatrienoic acid (5,6-DHET) and 5-hydroxyeicosatetraenoic acid (5-HETE), but increases in 9,10-EpOME and 12,13-EpOME as key markers that discriminated between ESRD patients and controls.…”

Inhibition of Soluble Epoxide Hydrolase for Renal Health

“…These human data suggest that sEH may be a therapeutic target for some renal diseases like IgA nephrology. However, Hu et al (2018) reported that the mEH (EPHX1) was downregulated while sEH was changed slightly in the whole blood cells of the uremic patients when compared with healthy controls. Therefore, further studies are needed to optimize a target renal disease for the follow-up clinical study of a sEH inhibitor.…”

“…However, mEH was found to modified slightly while sEH was up-regulated significantly in renal microvessels by the treatment of angiotensin-II infusion (Zhao et al, 2004). Recently, mEH was found to be decreased significantly while sEH altered non-significantly at mRNA level in the blood cells of the uremic patients when compared with healthy controls (Hu et al, 2018). The pathophysiological and pharmacological role of mEH in kidney diseases and other disorders needs further investigation.…”